A natural missense mutation in the signal transducer and activator of transcription (STAT) 5b gene was recently identified in association with a female patient presenting with severe growth failure and immune dysfunction. The mutation results in an alanine to proline substitution at residue 630 (A630P) in the src-homology-2 domain, a region essential for docking of STATs to phospho-tyrosines on activated receptors, STAT dimerization, and stabilization of phospho-STAT-DNA interactions.
T HE JANUS KINASE (JAK)-signal transducers and acti-
vators of transcription (STAT) signaling pathways, activated by multiple cytokine and growth factors, are fundamental to the regulation of genes involved in cell proliferation, immune surveillance, tumor suppression, and other biological activities. Ligand association with cytokine receptors results in JAK-induced tyrosine phosphorylation of the receptors, which act as docking sites for cytosolic proteins including the STATs. The STATs are subsequently phosphorylated on a single tyrosine by the JAKs, dimerize, and translocate to the nucleus, where they bind to DNA and participate in transcriptional regulation of targeted genes.
In mammals there are seven STATs (STAT1, -2, -3, -4, -5a, -5b, and -6). Although structurally similar, the unique properties of each STAT have been supported by gene disruption studies in rodent models (1) . Corresponding mutations in humans, however, are rare and have been identified only in the STAT1 gene (2, 3) and, recently, in the STAT5b gene (4, 5) . The autosomal recessive STAT5b mutations were identified in two unrelated female patients diagnosed with GH insensitivity syndrome, both of whom also presented with some degree of immune dysfunction. One of the STAT5b mutations was a frame-shift, which resulted in ablation of total STAT5b expression due to early termination of protein synthesis (5) , and the other was a missense mutation that altered Ala to Pro at residue 630 (A630P) (4) . STAT5b(A630P) was readily detectable in patient cells, albeit less well than wild-type STAT5b (4) .
Ala 630 is within the highly conserved src-homology 2 (SH2) domain of STAT5b (Fig. 1A) . The SH2 domain in STAT proteins has three well-characterized functions (1): 1) it per-mits docking of the STATs to phospho-tyrosines on activated receptors; 2) it permits phosphorylated STATs to hetero-or homodimerize before translocation to the nucleus; and 3) it stabilizes STAT-DNA interactions. Architecturally similar to other SH2 domains, the core of the STAT SH2 domain consists of an antiparallel ␤-sheet flanked by two ␣ helices (6) . The strictly conserved arginine, which recognizes the phosphate group of phosphotyrosines, is in strand-␤B, and residues in the loop connecting strands-␤B and -␤C provide the supporting structure for phosphate binding (6) . The proline substitution at residue 630 within strand-␤C is predicted to disrupt the ␤C-structure, thereby impairing the phosphate binding and possibly destabilizing STAT5b structure.
Significantly, in primary dermal fibroblasts carrying STAT5b(A630P), after stimulation by GH or interferon (IFN)-␥, both of which normally activate the JAK-STAT5b signaling pathways, phospho-STAT5 was not detected, and the STAT5b target gene, IGF-I, clearly was dysregulated (4, 7). The precise explanation for reduced IGF-I gene transcription remained uncertain because it could be the result of aberrant STAT5b(A630P) function(s) or simply reflect the presence of decreased levels of unstable STAT5b(A630P). The current studies provide evidence that, although mutant STAT5b(A630P) can be phosphorylated by non-receptorassociated kinases such as src, the phosphorylated STAT5b(A630P) is still unable to activate STAT5b-dependent target genes. This, together with new data demonstrating the inability of the mutant protein to be phosphorylated by GH and IFN-␥, is consistent with the hypothesis that the A630P mutation most likely prevents docking to activated cytokine receptors and prevents stable protein-DNA complex formation.
Materials and Methods Antibodies
Antibodies used were as follows: anti-phospho-tyrosine-STAT5 (Cell Signaling Technology, Beverly, MA); anti-STAT5a (L-20) and antiSTAT5b (G-2) (Santa Cruz Biotechnology, Santa Cruz, CA); goat sera, anti-FLAG M2, and anti-FLAG-M2-agarose gel (Sigma, St. Louis, MO); antimouse IgG and antirabbit IgG (Amersham-Pharmacia Biotech, Uppsala, Sweden); Hoechst 33342, fluorescein-conjugated goat antimouse, or antirabbit IgG (Molecular Probes, Eugene, OR). Anti-GH receptor (GHR) polyclonal antibody (GHRcyt-AL47) was generated as previously described (8) .
Cell culture
Human primary dermal fibroblasts, normal (CF) and carrying mutant STAT5b(A630P) (PF), have been described previously (4) . COS-7 cells (American Type Culture Collection, Manassas, VA), HEK293 (ATCC), and HEK293 stably transfected with the human GH receptor gene, HEK293(hGHR) (9), were maintained as recommended. Cells were treated with 100 U/ml IFN-␥ (Roche, Mannheim, Germany), 100 ng/ml human recombinant epithelial growth factor (EGF) (Sigma, St. Louis, MO), or 500 ng/ml recombinant human GH (generous gift from Genentech, Inc., South San Francisco, CA), as previously described (7).
Immunocytochemical analysis
Poly-d-lysine-coated eight-chamber slides (Becton Dickinson, Bedford, MA) were seeded with 6000 HEK293 or HEK239(hGHR) cells/ chamber, and transfected for 24 h, treated with GH (500 ng/ml) for 30 min before processing as previously described (10) . Appropriate primary (anti-FLAG or anti-pY-STAT5 at 1:500 dilution) and secondary antibodies were applied, and the nucleus was stained with Hoechst (1:1000 dilution). Immunofluorescence was observed as previously described (7, 10) .
Plasmids and adenovirus constructs
N-terminally FLAG-tagged STAT5b (F-STAT5b) and STAT5b(A630P) (F-A630P) constructs have been described previously (7) . Constructs carrying v-src or EGF receptor (EGFR) cDNAs were gifts from Drs. Brian Druker and Gayle Clinton, respectively (Oregon Health and Science University). The luciferase reporter construct, 8 ϫ GH response element (GHRE) from the rat Spi2.1 gene in pGL2 (pGHRE-LUC), was a gift from Drs. Joachim Woelfle and Peter Rotwein (Oregon Health and Science University). The generation of adenovirus carrying the rabbit recombinant GH receptor, Ad-rGHR, was similar to that previously reported (11) : rabbit GHR cDNA (a gift of W. Wood, Genentech), was N-terminally HA tagged, and resultant N-HA-GHR fragment (XbaI-PmeI) was subcloned into the XbaI and EcoRV sites of the adenoviral shuttle vector, pAdTrack-CMV. Final construction of Ad-rGHR followed the AdEasy system (Q-Biogene, Carlsbad, CA) protocol.
Transfection experiments
HEK293 and HEK293(hGHR) cells (ϳ60% confluent), plated on polyd-lysine-coated plates or slides (Becton Dickinson, San Jose, CA), were transiently transfected with pcDNA3.1 (1 g/well), F-STAT5b (1 g/ well), F-A630P (3 g/well), v-src (0.5 g/well), or EGFR (0.5 g/well) as indicated, using TransIT-LT1 (Mirus, Madison, WI). Transfections were performed in duplicates, at least three independent times, unless otherwise indicated. A higher concentration of F-A630P plasmid was necessary to generate final F-A630P protein concentrations immunologically equivalent to that of F-STAT5b protein. After 18 -24 h of transfection, cells were washed, serum starved for 6 h, and treated for 30 min as indicated.
Adenovirus infections of primary dermal fibroblasts
CF and PF cells were seeded at 5 ϫ 10 5 cells per 100-mm plate and grown to approximately 70% confluency. Infections with adenovirus constructs (vector, Ad-V; or Ad-rGHR) were carried out at a multiplicity of infection of 500, in ␣MEM supplemented with 5% fetal bovine serum. After 48 h of infection, the cultures were treated for 1 h with 500 ng/ml GH. Cells lysates were analyzed for expression and phosphorylation of recombinant proteins as indicated.
Inhibition of tyrosine phosphatases with sodium orthovanadate
Serum-starved HEK293(hGHR)-transfected cells were pretreated with 1 mm sodium orthovanadate (Na 3 VO 4 , Sigma) for 1 h and then treated with fresh serum-free HEK media containing 1 mm Na 3 VO 4 and GH (500 ng/ml) for the times indicated before cell lysis. Mock treatment was included as a control. HEK293 cells cotransfected with v-src and STAT5b (wild-type or mutant) were similarly processed.
Western immunoblot analysis
Cell lysates were solubilized in Triton X-100 lysis buffer as previously described (7). Equal quantities of protein (protein assay; Bio-Rad Laboratories, Hercules, CA), 30 g, were size fractionated on reducing 7% or 13% SDS-polyacrylamide gels and electroblotted onto nitrocellulose membranes. Western blots were processed with the appropriate primary and secondary antibodies, following manufacturers' protocols, and visualized by enhanced chemiluminescence (PerkinElmer Life Sciences, Inc., Boston, MA). In some cases, immunoprecipitation (IP) of total cell lysates (ϳ500 g), using anti-FLAG-M2-agarose beads, preceded Western immunoblot analysis.
Luciferase reporter assays
Luciferase (pGHRE-LUC)-transfected HEK293 or HEK293(hGHR) cells were analyzed for reporter activity using the luciferase assay system (Promega Corp., Madison, WI). Input DNA was a total of 3 g/well, adjusted accordingly with pcDNA3.1:0.5 g v-src, 1.0 g pGHRE-LUC, 2 g F-A630P, 0.5 g F-STAT5b, and 0.5 g EGFR. After treatment with GH, EGF, or IFN␥ for 24 h, cells were lysed and luciferase activities (normalized to total protein concentration) measured with a luminometer (Wallac, Inc., Gaithersburg, MD). Each experiment was performed at least two independent times, in triplicate. The results are reported as relative fold induction Ϯ sd relative to untreated conditions.
EMSA
Target DNA for pSTAT5b binding was the rat spi2.1 GHRE: 5Ј-ACGCTTCTACTAATCCATGTTCTGAGAAATCATCCAGTCTGCCCA-3Ј. The assay was performed with 1.5 g (normal EMSA) or 2.5 g (supershift assays) nuclear extract, 4 pmol nonbiotinylated target DNA, and 20 fmol 5Ј-biotinylated target DNA following the manufacturer's instructions (LightShift chemiluminescent EMSA kit; Pierce, Rockford, IL). Nuclear extracts were generated as described previously (12) and stored at Ϫ80 C. For supershift assay, excess (2 g) anti-FLAG M2 monoclonal antibody or mouse IgG (Sigma-Aldrich, St. Louis, MO) was included in the reactions. The DNA-protein complexes were resolved on native 5% polyacrylamide gels and detected as recommended by the manufacturer.
Results

GH-induced phospho-STAT5 is not detected in primary dermal fibroblasts carrying STAT5b(A630P)
In normal primary dermal fibroblasts (CF cells), both the GH and IFN␥ signaling systems preferentially tyrosine phosphorylate STAT5b over STAT5a (4, 7) . Phosphorylation of STAT5b by GH, however, is considerably less robust than that induced by IFN␥ (7) due, presumably, to low numbers of GHRs. Total GHR concentrations were increased, therefore, by infecting fibroblasts with adenovirus carrying rabbit GHR (Ad-rGHR). Upon GH treatment, phospho-STAT5 (pSTAT5) was consistently immunodetected in Ad-rGHRinfected normal fibroblasts, compared with fibroblasts infected with adenovirus control (Fig. 1B) . Primary dermal fibroblasts carrying the STAT5b(A630P) mutation (PF cells) were similarly infected with the adenovirus constructs, and, as shown in Fig. 1B , pSTAT5 still was not detectable by immunoblotting, despite overexpression of GHR.
FLAG-tagged mutant STAT5b (F-A630P) is not activated by GH in HEK293(hGHR)
The failure to detect pSTAT5 in the PF cells (Fig. 1B) suggested that STAT5b(A630P) could not be phosphorylated or that phosphorylated STAT5b(A630P) could not be detected because expression of the mutant protein was low (PF cells) in comparison with wild-type STAT5 (CF cells). To demonstrate definitively whether GH can induce phosphorylation of mutant STAT-5b(A630P), reconstitution experiments were performed in HEK293 cells stably transfected with hGHR. In HEK293(hGHR) cells, N-terminally FLAGtagged mutant (F-A630P) and wild-type (F-STAT5b) STAT5b were overexpressed to immunologically equivalent amounts ( Fig. 2A ) and response to GH treatment evaluated. Immunoblot analysis of vector (pcDNA3.1)-transfected cell lysates showed that GH treatment induced tyrosine phosphorylation of endogenous STAT5. When F-STAT5b was overexpressed, the band corresponding to pSTAT5 was intensified, suggesting F-STAT5b was also phosphorylated. In contrast, in cell extracts in which F-A630P was overexpressed, the pSTAT5 band was poorly detectable and similar to cells transfected with vector ( Fig. 2A) . IP of F-STAT5b and F-A630P confirmed GH-induced phosphorylation of F-STAT5b but not F-A630P (Fig. 2B) .
One explanation for the lack of detectable GH-induced phospho-F-A630P (p-F-A630P) is that the A630P mutation rendered the protein more vulnerable to dephosphorylation. To determine whether this was the case, transfected cells were preexposed to Na 3 VO 4 , a general tyrosine phosphatase inhibitor, before GH treatment. In the absence of Na 3 VO 4 , phosphorylation of wild-type F-STAT5b was significantly reduced 18 h after GH treatment (Fig. 2C) , but the presence of Na 3 VO 4 prolonged and enhanced detectable GH-induced p-F-STAT5b. Unlike p-F-STAT5b, however, Na 3 VO 4 treatment did not enhance detection of p-F-A630P. Clearly, the lack of detectable p-STAT5b(A630P) was not due to a more rapid dephosphorylation process.
The activity of GH-induced p-F-STAT5b was measured by luciferase reporter assays, using the response element, GHRE, from the rat Spi2.1 gene, which is specific for STAT5b (13, 14) . GH induced a modest 1.8-fold increase in luciferase activity in cells transfected with pcDNA3.1, whereas a greater than 20-fold induction in reporter activity was observed in GH-treated cells transfected with F-STAT5b (Fig.  2D) . As predicted, in cells transfected with F-A630P, GHinduced reporter activity was similar to that of vector control (Fig. 2D) . Expression of mutant and wild-type STAT5b in these assays was equivalent by immunoblot analysis (data not shown).
F-A630P is not activated by IFN␥ in HEK293
We previously demonstrated that IFN␥ could not induce phosphorylation of STAT5b(A630P) in primary fibroblasts, resulting in dysregulation of the IGF-I target gene (7). These earlier observations are extended in reconstitution studies using HEK293 cells. IFN␥ treatment, like GH treatment, resulted in tyrosine phosphorylation of wild-type F-STAT5b but not of mutant F-A630P (Fig. 3A) . Furthermore, whereas IFN␥-induced p-F-STAT5b was able to drive luciferase reporter activity, F-A630P could not (Fig. 3B) .
Phosphorylation of F-A630P by src-mediated systems
Both GH and IFN␥ activation of the JAK-STAT5b signaling pathways require initial recruitment of STAT5b, which, via their SH2 domain, dock to phospho-tyrosines (pY) on the receptors. The receptor-associated JAKs subsequently tyrosine phosphorylate the docked STAT5b at Y699. Since STAT5b(A630P) could not be phosphorylated by activatedreceptor-JAK2 systems, we asked whether STAT5b(A630) could be phosphorylated through non-receptor-mediated mechanism(s), and, if phosphorylated, could it function as a transcription factor. To evaluate this possibility, a constitutively active nonreceptor tyrosine kinase, v-src, was cotransfected with F-STAT5b or F-A630P in HEK293 cells, and pSTAT5 analyzed. As shown in Fig. 4A , the presence of v-src resulted in phosphorylation of not only F-STAT5b but also mutant F-A630P, although p-F-A630P was reproducibly less well immunodetected, compared with that of wild type. Pretreatment of transfected cells with Na 3 VO 4 did not further enhance detectable p-F-A630P (Fig. 4B) . These results support the hypothesis that Y699 on the mutant protein is available for phosphorylation, although efficiency may be lowered.
It is possible, however, that even proteins not normally phosphorylated become phosphorylated when v-src is highly overexpressed. We therefore examined the EGF signaling pathway, which, unlike the GH and IFN␥ pathways, can induce tyrosine phosphorylation of STAT5b by activating endogenous c-src (15, 16) . Coexpression of EGFR and F-STAT5b in HEK293 cells resulted in a low level of detectable p-F-STAT5b, which was significantly enhanced with EGF treatment (Fig. 4C) . No p-F-A630P was detected when EGFR was coexpressed with F-A630P, but on addition of
FIG. 2. F-A630P
is not activated by GH in reconstitution experiments. HEK293(hGHR) cells were transfected with plasmids pcDNA3.1 (Invitrogen Life Technologies, Carlsbad, CA), F-STAT5b, or F-A630P and treated with GH for 30 min or as indicated. A, Cell lysates were collected and analyzed by Western immunoblot (WIB). Antibodies used are indicated. B, Recombinant FLAG-tagged proteins were IP from 500 g of total protein before WIB analysis. C, Transfected cells were pretreated with 1 mM Na 3 VO 4 or media for 1 h before treatment with GH (with or without Na 3 VO 4 ). All 0 time points also reflect no GH treatment. Cell lysates were IP with ␣FLAG before WIB analysis. D, GHRE(Spi2.1)-luciferase reporter activity. Cells, cotransfected with pGHRE-LUC, were treated with or without GH for 24 h and cell lysates collected for determination of luciferase activity. Results are reported as relative fold induction, compared with untreated (ϪGH, given an arbitrary value of 1) Ϯ SD, from four independent experiments, each performed in triplicate.
FIG. 3. F-A630P
is not activated by the IFN␥ signaling pathway in reconstitution experiments. HEK293 cells were transfected with plasmids pcDNA3.1, F-STAT5b, or F-A630P and treated with IFN␥ (100 U/ml) for 30 min. A, Cell lysates were collected and recombinant FLAG-tagged proteins were IP from 500 g total protein before Western immunoblot (WIB) analysis. B, GHRE(Spi2.1)-luciferase reporter activity. pGHRE-LUC cotransfected cells were treated with or without IFN␥ for 24 h and cell lysates collected for determination of luciferase activity. Results are reported as relative fold induction to untreated (ϪIFN␥, given an arbitrary value of 1) Ϯ SD, from three independent experiments, each performed in triplicate.
EGF, p-F-A630P was readily and reproducibly immunodetected, albeit consistently at levels lower than those observed with F-STAT5b (Fig. 4C) . Identical results were obtained in reconstitution experiments using COS-7 cells, which had high levels of endogenous EGFR (data not shown). Altogether, the results suggest that mutant STAT5b(A630P) can be tyrosine phosphorylated under limited situations.
Src-induced p-F-A630P can translocate to the nucleus but cannot bind DNA
To determine whether p-F-A630P was capable of translocating to the nucleus, immunocytochemical and cellular fractionation studies were performed on HEK293 cells cotransfected with v-src and vector, wild-type, or mutant STAT5b. Immunofluorescent staining of cells indicated that pSTAT5 was not detectable when v-src was cotransfected with vector only (Fig. 5A, top panels) . In the absence of v-src, pSTAT5 was also not immunodetected, although FLAG-tagged wild-type and mutant STAT5b were observed in the cytoplasm of cells overexpressing the proteins (data not shown). When v-src was cotransfected with F-STAT5b, pSTAT5 was readily detected and appeared to be nuclear (Fig. 5A, middle panels) . Surprisingly, similar observations were made in cells cotransfected with v-src and mutant F-A630P (Fig. 5A, bottom  panels) .
The nuclear localization of v-src-activated p-F-A630P was not due simply to overexpresssion of F-A630P because F-A630P was not detected in the nucleus of GH-treated HEK293(hGHR) cells overexpressing F-A630P but was readily detected in the cytoplasm of the cells (Fig. 5B) . Under the same conditions, wild-type F-STAT5b was immunodetected in the nucleus only after GH treatment (Fig. 5B) .
The results from immunocytochemical studies were confirmed by cellular fractionation studies. Immunoblot analysis of F-STAT-5b or F-A630P, IP from fractionated HEK293 cells cotransfected with v-src, indicated both p-F-STAT-5b and p-F-A630P were present in the nuclear fractions, although proportionally less p-F-A630P was detected. We concluded from these experiments that v-src-induced p-F-A630P can translocate to the nucleus.
We next evaluated whether v-src-mediated p-F-A630P could bind DNA. Analysis by EMSA demonstrated that F-STAT5b gel shifted GHRE in the presence of v-src (Fig. 6A , lane 12). The same gel-shifted band was detected when F-STAT5b was activated by GH (Fig. 6A, lane 3) and absent in unstimulated F-STAT5b (Fig. 6A, lanes 1, 2, 10 , and 11). Specificity of binding was indicated by loss of the gel-shifted band in competition experiments with unlabeled GHRE oligonucleotides (Fig. 6A, lanes 4 and 13) . Furthermore, supershifting of the respective band was achieved with anti-Flag antibody (Fig. 6B, lanes 2, 4) but not with excess mouse IgG (Fig. 6B, lane 5) . In stark contrast, v-src-activated F-A630P did not gel shift the GHRE (Fig. 6A) , suggesting that, despite the unexpected ability to translocate to the nucleus, p-F-A630P was unable to stably bind DNA and therefore unlikely to be able to act as a transcription factor.
Src-induced p-F-A630P cannot drive GHRE(Spi2.1) luciferase-reporter activity
The inability of p-F-A630P to act as a transcription factor was confirmed in vitro using luciferase reporter assays (Fig.  6, C and D) . In vector-transfected HEK293 cells, only a modest 1.5-fold increase in luciferase activity was observed on EGF treatment or with v-src. In the presence of F-STAT5b, EGF or v-src treatment resulted in a 7-fold increase in luciferase activity relative to untreated conditions. In contrast, neither EGF treatment nor v-src could induce F-A630P to drive luciferase activity above that of background (Fig. 6,  and D) .
Discussion
The identification of a natural missense mutation in STAT5b associated with severe growth failure and immune dysfunction (4) pointed to the biological importance of STAT5b but, simultaneously, raised fundamental questions concerning the impact(s) this unique mutation had on STAT5b function(s). In the STAT5b
Ϫ/Ϫ mouse model, targeted disruption of the STAT5b gene ablated expression of STAT5b, and the effect of absence of STAT5b was loss of the sexual dimorphic body growth rates characteristic of normal mice, with STAT5b Ϫ/Ϫ male mice reduced to the size of A, Cell lysates were collected, FLAG-tagged protein IP from 500 g total protein, and analyzed by Western immunoblot (WIB). Antibodies used are indicated. B, Transfected cells were treated with 1 mM Na 3 VO 4 or media for 6 h before cell lysate collection. Cell lysates were IP with ␣-FLAG before WIB analysis. C, Cells were cotransfected with EGFR and treated with or without EGF (100 ng/ml) for 30 min before collecting cell lysates. FLAG-tagged proteins were IP from 500 g total protein and analyzed by WIB.
female mice and displaying marked changes in liver gene expression, whereas the size of female mice remained unaltered (17) . Aberrancy in immune function was subsequently noted (18 -22) , although the most severe immunological changes were those observed in mice lacking both STAT5a and STAT5b (23, 24) . Clearly the human phenotype is somewhat different from that reported in the rodent knockout model because the human female patient was both severely growth retarded and immunologically impaired. Whether this reflects true interspecies differences of STAT5 function, or is the consequence of the specific mutation involved, remains to be resolved, although it is of note that the second case of STAT5b mutation reported, also in a female, had a similar growth and immune phenotype (5) .
In this report, we confirm and extend our previous observations regarding the inability of ligand-dependent signaling pathways to activate STAT5b(A630P) (4, 7) and provide new data demonstrating that, via ligand-independent mechanisms, STAT5b(A630P) can be phosphorylated and translocate to the nucleus but remains functionally impaired as a transcription factor. Activation of STAT5b by type I and type II cytokine receptors, represented by the GH and IFN␥ receptors, respectively, requires the recruitment of STAT5b to phospho-tyrosines on ligand-activated receptors before phosphorylation of STAT5b by JAK2. The lack of detectable phospho-tyrosyl-STAT5b(A630P) in both reconstitution experiments and native state suggests that the A630P mutation affects these initial steps in signal transduction. Evidence in support of this hypothesis comes from two observations: 1) STAT5b(A630P) can be tyrosine phosphorylated by non-receptor-associated constitutively active v-src; and 2) Na 3 VO 4 treatment does not enhance detection of GH-induced phospho-STAT5b(A630P), indicating that an increased vulnerability to dephosphorylation is not the explanation for lack of detectable phopho-STAT5b(A630P). Attempts to determine whether mutant STAT5b(A630P) could dock to GH-activated GHR (using reciprocal co-IP techniques) were inconclusive because the wild-type STAT5b did not consistently co-IP with GHR (data not shown). Nevertheless, the combination of a disrupted SH2 domain and phosphorylation by JAK2-independent, nonreceptor kinase mechanisms would support the concept that STAT5b(A630P) is unlikely to dock normally to ligand-activated receptors.
The tyrosine phosphorylation of STAT5b(A630P) by srcmediated systems is consistent with cumulative reports demonstrating activation of STAT5a/b via JAK2-independent mechanisms involving nonreceptor kinases (15, (25) (26) (27) (28) . The p-STAT5b(A630P) detected reflected phosphorylation at Y699 because the commercially available anti-pSTAT-5 antibody we used detects STAT5 only when phosphorylated at Y694 (STAT-5a) or the equivalent Y699 (STAT-5b) (29) . Indeed, all published reports indicate Y699 as the main site phosphorylated by the src family of kinases (16, 26, 27) . It is probable that tyrosines other than Y699 were also phosphorylated in STAT5b(A630P), as has been demonstrated for rat STAT5b, in which v-src additionally phosphorylated Y724 and Y679 (26) and, for human STAT5b, EGF-induced phosphorylation of Y725, Y740, and Y743, in addition to Y699 (16, 29) . The biological consequences of phosphorylated tyrosines other than Y699, however, are unclear, although alterations in the pattern of nuclear localization and gene expression have been suggested (26) .
One consequence of src-mediated phosphorylation of mutant STAT5b(A630P) was its translocation to the nucleus, although whether this occurs in vivo remains to be established. Our results indicate that the nuclear translocation signal, proposed to be either in the DNA binding domain (30) or the N-terminal region (31) , was unaffected by the A630P mutation. Furthermore, the results implied that, according to accepted paradigm, homodimers of p-STAT5b(A630P) formed before translocation. It is unclear, at present, whether STAT5b(A630P) could form dimers through the accepted mechanism involving reciprocal binding of pY via the SH2 domain. Interestingly, SH2-independent dimerization mechanisms were suggested in a recent study demonstrating that nonphosphorylated STAT4 formed dimers through its N domain (32) .
Nuclear p-F-STAT5b(A630P) could not drive gene ex- Arrow indicates the gel-shifted band. B, Specificity of F-STAT5b-GHRE complex (lower arrow) was determined by supershifting (upper arrow) with anti-FLAG antibody or mouse IgG (2 g/reaction). C, EGFR cotransfected cells (as described in Fig. 4) were treated with or without EGF for 24 h and cell lysates collected for determination of luciferase activity. Results are reported as relative fold induction to untreated (ϪEGF, given an arbitrary value of 1) Ϯ SD from two independent experiments, each performed in triplicate. D, Luciferase activity was determined from v-src-cotransfected cells (see Fig. 4 ). Results (fold induction Ϯ SD) are relative to pcDNA3.1 basal activity (set arbitrarily as 1), performed three independent times, in triplicate.
pression because, unlike the phosphorylated wild-type, the mutant STAT5b appeared to be unable to bind DNA. In gel-shift assays, only activated F-STAT5b bound to the GHRE, which could be further supershifted with anti-FLAG antibody. The inability of p-F-STAT5b(A630P) to bind DNA in steady-state in vitro assays is consistent with the proposed role of the SH2 domain in stabilizing STAT-DNA interactions (6) . The A630P mutation rendered STAT5b(A630P) poorly detected in PF cells due, most probably, to the considerably shortened half-life of STAT5b(A630P) (3 h), compared with wild-type STAT5b (Ͼ24 h) (33) . We have now demonstrated that, even if STAT5b(A630P) is expressed more abundantly, the mutant protein remains functionally impaired. Interestingly, overexpressing wild-type F-STAT5b in PF cells can re-regenerate the GH signaling pathway (data not shown), suggesting that STAT5b(A630P) does not appear to exert an obvious negative effect on the function(s) of wild-type STAT5b. This would be consistent with the heterozygous state of the parents of the patient, who are of normal stature and with no apparent immune complications (4) .
Finally, the importance of STAT5b for human statural growth has recently been verified by the identification of a second case of mutant STAT5b associated with severe growth retardation and GH insensitivity/IGF deficiency (5). The identified frameshift mutation ablated detectable STAT5b as a consequence of early termination of protein synthesis. The phenotype of immune dysfunction in both cases indicated that STAT5b is also critical for normal immunity. Altogether, STAT5b(A630P) appears to be functionally equivalent to an absence of the STAT5b protein.
In conclusion, the A630P mutation disrupted the SH2 architecture such that the mutant STAT5b: 1) most likely cannot dock normally to phospho-tyrosines on ligandactivated receptors, thus preventing phosphorylation by these systems; and 2) cannot form stable STAT5b-DNA interactions, even if phosphorylated and nuclear localized. Because STAT5b(A630P) has proven to be an inefficient signal transducer and transcription factor, the detrimental impacts on signaling pathways important for normal growth and immunity explain, in part, the complex clinical phenotype of GH insensitivity/IGF deficiency and immune dysfunction.
